Idiopathic Intracranial Hypertension 

  • Author: Mark S Gans, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Jan 5, 2012
 

Background

The presentation of a patient with symptoms of increased intracranial pressure and papilledema should be considered a clinical emergency until neuroimaging study results confirm the presence or absence of an intracranial mass.

A significant number of patients presenting in the above fashion whose neuroimaging study results do not reveal a mass lesion are diagnosed with idiopathic intracranial hypertension. Although idiopathic intracranial hypertension, pseudotumor cerebri, and benign intracranial hypertension are synonymous with this diagnosis, the preferred term is idiopathic intracranial hypertension.

The diagnostic criteria, including those of the modified Dandy criteria as described by Dandy in 1937 and later modified by Smith in 1985, are as follows: there are symptoms and signs of increased intracranial pressure; there are no localizing neurologic signs (with the exception of a unilateral or bilateral sixth nerve paresis); cerebrospinal fluid can show increased pressure, but there are no cytologic or chemical abnormalities; and normal to small symmetric ventricles must be demonstrated. Subsequent additions to these criteria include the following: the diagnostic lumbar puncture should be in the lateral decubitus position; MRI/venography should be included to rule out intracranial venous sinus thromboses; and other causes of intracranial hypertension should be ruled out.[1, 2, 3]

Next

Pathophysiology

The pathophysiology of this disorder is unclear. A relative resistance to the absorption of cerebrospinal fluid across the arachnoid villi is widely presumed to be present. Other theories support an abnormality in the cerebral circulation with a resulting increase in the brain's water content. The subsequent increase in the intracranial pressure is transmitted to the structures within the intracranial cavity, including the optic nerves. Unfortunately, because of the difficulty in applying animal models of cerebrospinal fluid dynamics to humans, the underlying pathophysiology in idiopathic intracranial hypertension remains unclear.

Current hypotheses include the link between relatively obstructive segments in the distal transverse sinus and idiopathic intracranial hypertension or the presence of increased arterial inflow with an accompanying low-grade stenosis of the transverse sinus.[4, 5]

The disease commonly occurs in women who are overweight. The role of obesity in this disorder is unclear. In some instances, obesity and idiopathic intracranial hypertension may be familial.[6] Obesity has been proposed to increase intra-abdominal pressure, which, in turn, raises cardiac filling pressures. This rise in pressure leads to impeded venous return from the brain (due to the valveless venous system that exists from the brain to the heart) with a subsequent elevation in intracranial venous pressure. If not treated appropriately, chronic interruption of the axoplasmic flow of the optic nerves with ensuing papilledema due to this pressure may lead to irreversible optic neuropathy.[7]

Previous
Next

Epidemiology

Frequency

United States

Studies of American-based populations have estimated that the incidence of idiopathic intracranial hypertension ranges from 0.9-1.0 per 100,000 in the general population. This incidence rate increases to 1.6-3.5 per 100,000 in women and to 7.9-20 per 100,000 in women who are overweight.[1, 3, 5]

International

The incidence of idiopathic intracranial hypertension is variable from country to country. Because of the relation of the disease to body habitus, its occurrence varies according to the incidence of obesity in the respective region.

Mortality/Morbidity

  • The morbidity of this disorder is mainly related to the effects of papilledema on visual function.[8]
  • If left untreated, long-standing disc edema results in an irreversible optic neuropathy with accompanying constriction of the visual field and loss of color vision.[9, 10]
  • In end-stage papilledema, central visual acuity is also involved.

Sex

A strong predilection of this disease exists for women. More than 90% of patients with idiopathic intracranial hypertension are women of childbearing age.[5] However, men with idiopathic intracranial hypertension are twice as likely as women to lose visual function due to their papilledema. Thus, the visual function of men with idiopathic intracranial hypertension must be followed more closely to avoid irreversible damage.[11]

Age

Although idiopathic intracranial hypertension may affect individuals of any age, most patients with this disease present in the third decade of life.[5]

Idiopathic intracranial hypertension does occur in the pediatric population[12] ; these younger patients are often not obese.

Previous
 
 
Contributor Information and Disclosures
Author

Mark S Gans, MD  Associate Professor, Director of Neuro-Ophthalmology, Department of Ophthalmology, McGill University; Clinical Director, Department of Ophthalmology, Adult Sites, McGill University Hospital Center, Interim Chairman of the Department of Ophthalmology, McGill University

Mark S Gans, MD is a member of the following medical societies: American Academy of Ophthalmology, Canadian Medical Association, Canadian Ophthalmological Society, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Edsel Ing, MD, FRCSC  Associate Professor, Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine; Consulting Staff, Toronto East General Hospital, Canada

Edsel Ing, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Society of Ophthalmic Plastic and Reconstructive Surgery, Canadian Ophthalmological Society, North American Neuro-Ophthalmology Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Brian R Younge, MD  Professor of Ophthalmology, Mayo Clinic School of Medicine

Brian R Younge, MD is a member of the following medical societies: American Medical Association, American Ophthalmological Society, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol. Jun 2004;24(2):138-45. [Medline].

  2. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. Nov 26 2002;59(10):1492-5. [Medline].

  3. Miller NR, Newman NJ. Pseudotumor cerebri (benign intracranial hypertension). In: Walsh and Hoyt's Clinical Neuro-Ophthalmology. Vol 1. 5th ed. 1999:523-38.

  4. Bateman GA, Stevens SA, Stimpson J. A mathematical model of idiopathic intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg. Mar 2009;110(3):446-56. [Medline].

  5. Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri). Curr Neurol Neurosci Rep. Mar 2008;8(2):87-93. [Medline].

  6. Corbett JJ. The first Jacobson Lecture. Familial idiopathic intracranial hypertension. J Neuroophthalmol. Dec 2008;28(4):337-47. [Medline].

  7. Daniels AB, Liu GT, Volpe NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. Apr 2007;143(4):635-41. [Medline].

  8. Digre KB, Nakamoto BK, Warner JE, Langeberg WJ, Baggaley SK, Katz BJ. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache. Feb 2009;49(2):185-93. [Medline].

  9. Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. Aug 1982;39(8):461-74. [Medline].

  10. Ney JJ, Volpe NJ, Liu GT, Balcer LJ, Moster ML, Galetta SL. Functional Visual Loss in Idiopathic Intracranial Hypertension. Ophthalmology. Jul 28 2009;[Medline].

  11. Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology. Jan 27 2009;72(4):304-9. [Medline].

  12. Jiraskova N, Rozsival P. Idiopathic intracranial hypertension in pediatric patients. Clin Ophthalmol. Dec 2008;2(4):723-6. [Medline].

  13. Gonzalez-Hernandez A, Fabre-Pi O, Diaz-Nicolas S, Lopez-Fernandez JC, Lopez-Veloso C, Jimenez-Mateos A. [Headache in idiopathic intracranial hypertension]. Rev Neurol. Jul 1-15 2009;49(1):17-20. [Medline].

  14. Mollan SP, Ball AK, Sinclair AJ, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol. 2009;62(2):105-8. [Medline].

  15. Lin A, Foroozan R, Danesh-Meyer HV, De Salvo G, Savino PJ, Sergott RC. Occurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology. Dec 2006;113(12):2281-4. [Medline].

  16. Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. Dec 1998;105(12):2313-7. [Medline].

  17. Brazis PW. Clinical review: the surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension). Cephalalgia. Dec 2008;28(12):1361-73. [Medline].

  18. Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol. May 1993;111(5):632-5. [Medline].

  19. Sinclair AJ, Kuruvath S, Sen D, et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia. Dec 2011;31(16):1627-33. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.